RxDoctor Payments Data

Howard Hochster, MD

Internal Medicine · Bronx, NYNPI 1497768808

Payments from drug & device makers

$120,177in general payments, 2019–2025

Across 17 payments — averaging $7069.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$112K
  • AstraZeneca$8K
  • Novo Nordisk$106
  • Pfizer$24
  • Exact Sciences$23
  • Boehringer Ingelheim$22
  • plus $51 from 3 others

What the payments were for

  • Food & beverage$328100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$120,177 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$515,493
Medicare patients
406
Services billed
7,202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide88$155,849
EliquisApixaban189$147,793
OzempicSemaglutide71$122,708
JardianceEmpagliflozin99$89,475
JanuviaSitagliptin Phosphate34$38,706
TrulicityDulaglutide27$36,369
XareltoRivaroxaban23$34,825
FarxigaDapagliflozin Propanediol25$30,404
EntrestoSacubitril/Valsartan51$29,451
Invega SustennaPaliperidone Palmitate11$26,744
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog40$17,278
MyrbetriqMirabegron33$15,578
JanumetSitagliptin Phos/Metformin Hcl30$15,198
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$13,350
BrilintaTicagrelor19$8,369

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$106$278,558159 claims
PfizerEliquis$24$147,793189 claims
Boehringer IngelheimJardiance$22$89,47599 claims
AstraZenecaFarxiga, Brilinta$8,332$38,77344 claims
Lilly USA, LLCTrulicity$19$36,36927 claims
NovartisEntresto$18$29,45151 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →